Dabigatran (Pradaxa in Australia, Europe, USA and Canada (previously was Pradax in Canada, name change to Pradaxa as of January 2013), Prazaxa in Japan) is an oral anticoagulant from the class of the direct thrombin inhibitors. It is used for various clinical indications, and in some cases it offers an alternative to warfarin as the preferred orally administered anticoagulant ("blood thinner"), since it does not require frequent blood tests for international normalized ratio monitoring, while offering similar results in terms of efficacy. No specific way exists to reverse the anticoagulant effect of dabigatran in the event of a major bleeding event, unlike warfarin. It was developed by the pharmaceutical company Boehringer Ingelheim.Source: Wikipedia
Patients are most commonly prescribed dabigatran to treat blastomycosis, rabies, west nile virus, and pick disease.